Effects of two tetrahydroisoquinolines (YS-49 and YS-51) on experimental disseminated intravascular coagulation induced by lipopolysaccharide in rats

Arzneimittel-Forschung/Drug Research

Volumn 54, Issue 11, 2004, Pages 705-710

  Pyo, Mi Kyung ^a,d   Yun Choi, Hye Sook ^a   Chang, Ki Churl ^b   Lee, Duck Hyung ^c  

^a Seoul National University   (South Korea)

^b Gyeongsang National University School of Medicine   (South Korea)

^c Sogang University   (South Korea)

^d ES Life Science Research Institute   (South Korea)

Author keywords

1 ( Naphthylmethyl) 6,7 dihydroxy 1, 2,3,4 tetrahydroisoquinoline; 1 ( Naphthylmethyl) 6,7 dihydrosy 1,2,3,4 tetrahydroisoquinoline; CAS 132836 42 1; CAS 213179 96 5; YS 49, effect on disseminated intravascular coagulation, rat

Indexed keywords

1 (ALPHA NAPHTHYLMETHYL) 6,7 DIHYDROXY 1,2,3,4 TETRAHYDROISOQUINOLINE; 1 (BETA NAPHTHYLMETHYL) 6,7 DIHYDROXY 1,2,3,4 TETRAHYDROISOQUINOLINE; ANTICOAGULANT AGENT; ASPARTATE AMINOTRANSFERASE; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; FIBRINOGEN DEGRADATION PRODUCT; LIPOPOLYSACCHARIDE; NITROGEN; TETRAHYDROISOQUINOLINE DERIVATIVE; UNCLASSIFIED DRUG; UREA; YS 49; YS 51;

ANIMAL MODEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFECT; DRUG STRUCTURE; FIBRINOGEN BLOOD LEVEL; KIDNEY FUNCTION; LIVER FUNCTION; MALE; MULTIPLE ORGAN FAILURE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; RAT; THROMBOCYTE COUNT; UREA NITROGEN BLOOD LEVEL;

EID: 9944245186     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1297027     Document Type: Article

References (32)

1. ten Gate, H., Pathophysiology of disseminated intravascular coagulation in sepsis. Crit. Care Med. 28, S9 (2000)
2. Müller-Berghaus, G., Pathophysiologic and biochemical events in disseminated intravascular coagulation: Dysregulation of procoagulant and anticoagulant pathway. Sem. Thromb. Hemost. 15, 58 (1989)
3. Levi, M., de Jonge, E., van der Poll, T. et al., Novel approaches to the management of disseminated intravascular coagulation. Crit. Care Med. 28, S20 (2000)
4. Baglin, T., Disseminated intravascular coagulation: Diagnosis and treatment. Br. Med. J. 312, 683 (1996)
5. Opal, S., Thijs, L., Cavaillon, J. M. et al., Relationships between coagulation and inflammatory processes. Crit. Care. Med. 28, S81 (2000)
6. Opal, S. M., Phylogenetic and functional relationships between coagulation and the innate immune response. Crit. Care Med. 28, S77 (2000)
7. Kang, Y. J., Koo, E. B., Lee, Y. S. et al., Prevention of the expression of inducible nitric oxide synthase by a novel positive inotropic agent, YS-49, in rat vascular smooth muscle and RAW 264.7 macrophages. Br. J. Pharmacol. 128, 357 (1999)
8. Jung, T. H., Lee, Y. S., Kang, Y. J. et al., Inhibition of tumor necrosis factor-α mRNA expression by a limited series of tetrahydroisoquinolines in mouse peritoneal macrophages. Korean J. Physiol. Pharmacol. 4, 325 (2000)
9. Kang, Y. J., Seo, S. I., Yun-Choi, H. S., A synthetic isoquinoline alkaloid, 1-(β-naphthylmethyl)-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (YS-51), reduces inducible nitric oxide synthase expression and improves survival in a rodent model of endotoxic shock. J. Pharmacol. Exp. Ther. 301, 561 (2002)
10. Yun-Choi, H. S., Pyo, M. K., Park, K. M., Antithrombotic effects of YS-49 and YS-51-1-naphthylmethyl analogs of higenamne. Thromb. Res. 104, 249 (2001)
11. Lee, Y. S., Kim, C. H., Yun-Choi, H. S. et al., Cardiovascular effect of a naphtylmethyt substituited tetrahydroisoquinoline, YS 49, in rat and rabbit. Life Sci. 55, PL415 (1994)
12. Chang, K C., Kang, Y. J., Lee, Y. S., Pharmacological characterization of synthetic tetrahydroisoquinoline alkaloids, YS 51 and YS 55, on the cardiovascular system. Korean J. Physiol. Pharmacol. 2, 461 (1998)
13. Chong, W. S., Lee, Y. S., Kang, Y. J., Comparison of inodilator effect of higenamine, YS-49, YS-51, tetrahydroisoquinoline analogs, and dobutamine in the rat. Korean J. Physiol. Pharmacol. 2, 323 (1998)
14. Yun-Choi, H. S., Pyo, M. K., Chang, K. C. et al., The effects of higenamine on LPS-induced experimental disseminated intravascular coagulation (DIC) in rats. Planta Med. 68, 326 (2002)
15. Kim, Y. S., Pyo, M. K., Park, K. M. et al., Dose dependency of earthworm powder on antithrombotic and fibrinolytic effects. Arch. Pharm. Res. 4, 374 (1998)
16. Kawamura, M., Terashita, Z., Imura, Y. et al., Inhibitory effect of TGV-309, a novel platelet activating factor (PAF) antagonist, on endotoxin-induced disseminated intravascular coagulation in rats: Possible role of PAF in tissue factor generation. Thromb. Res. 70, 281 (1993)
17. Aoki, Y., Ota, M., Katsuura, Y. et al., Effect of activated human protein C on disseminated intravascular coagulation induced by lipopolysaccharide in rats. Arzneim.-Forsch./Drug Res. 50 (II), 809 (2000)
18. Fujita, M., Izutani, W., Komurasaki, Y., Effect of urinary protein C inhibitor on lipopolysaccharide induced disseminated intravascular coagulation in rats. Thromb. Haemost. 84, 54 (2000)
19. Onaya, J., Kyogashima, M., Sunose, A. et al., Effects of dermatan sulfate, a heparin cofacter II mediated thrombin inhibitor, on the endotoxin-induced disseminated intravascular coagulation model in the rat: comparison with low-molecular weight heparin, nafamostat mesilate and argathroban. Jpn. J. Pharmcol. 76, 397 (1998)
20. Pernerstorfer, T., Hollenstein, U., Stohlawetz, P. et al., Lepirudin blunts endotoxin induced coagulation activation. Blood 95, 1729 (2000)
21. Ito, T., Asai, F., Oshima, T. et al., Role of activated platelets in endotoxin induced DIC in rats. Thromb. Res. 50, 735 (1990)
22. Fujishima, Y., Yokota, K., Sukamoto, T., The effect of danaparoid sodium (danaparoid) on endotoxin-induced experimental disseminated intravascular coagulation (DIC) in rats. Thromb. Res. 91, 221 (1998)
23. ten Gate, H., Schoenmakers, S. H., Franco, R. et al., Microvascular coagulophathy and disseminated intravascular coagulation. Crit. Care Med. 29, S95 (2001)
24. Faust, S. N., Heyderman, R. S., Levin, M., Coagulation in severe sepsis: A central role for thrombomodulin and activated protein C. Crit. Care Med. 29, S62 (2001)
25. Gawaz, M., Fateh-Moghadam, S., Pilz, G. et al., Platelet activation and interaction with leukocyte in patients with sepsis or multiple organ failure. Eur. J. Clin. Invest. 25, 843 (1995)
26. Java, R., Solomkin, J., In: Sepsis and multiorgan failure, A. Fein (ed.) pp. 74. Williams & Wilkins, Baltimore (1997)
27. Dinarello, C., Cytokines as mediators in the pathogenesis of septic shock. Curr. Top. Microbiol. Immunol. 216, 133 (1996)
28. Cobb, J., Danner, R., Nitric oxide and septic shock. J. Am. Med. Assoc. 275, 1192 (1996)
29. Lorente, J., Landin, L., Pablo, R., L-arginine pathway in sepsis syndrome. Crit. Care Med. 21, 1287 (1993)
30. Astiz, H. E., Rackow, E. C., Septic shock. Lancet 351, 1501 (1998)
31. Bernard, G. R., Vincent, J. L., Laterre, P. F. et al., Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344, 699 (2001)
32. Chaby, R., Strategies for the control of LPS-mediated pathophysiological disorders. Drug Discov. Today 4, 209 (1999)